A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab

Emily Su, Vikash S. Oza, Paul Latkany

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Vogt-Koyanagi-Harada (VKH) disease is uncommon in the pediatric population and can have an aggressive course with serious visual sequelae. A 12-year-old Han Chinese American female, who presented with mild headaches and panuveitis with diffuse serous retinal detachments, was diagnosed with VKH. Despite treatment with a combination of high-dose systemic corticosteroids, intravitreal triamcinolone injection, and mycophenolate mofetil, ocular inflammation was inadequately controlled. Addition of adalimumab allowed for inflammation remission, improvement of vision, and tapering of systemic corticosteroids. Escalation of immunosuppression until remission appears to be critical in this population. Further research is needed to understand the complex pathophysiology of VKH and investigation for similar efficacy of other anti-tumor necrosis factor-alpha agents will need to be performed.

Original languageEnglish
Pages (from-to)945-950
Number of pages6
JournalJournal of the Formosan Medical Association
Volume118
Issue number5
DOIs
StatePublished - May 2019
Externally publishedYes

Keywords

  • Adalimumab
  • Mycophenolate mofetil
  • Pediatric
  • Vogt-Koyanagi-Harada (VKH)

Fingerprint

Dive into the research topics of 'A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab'. Together they form a unique fingerprint.

Cite this